267 related articles for article (PubMed ID: 31934898)
1. Catecholaminergic Polymorphic Ventricular Tachycardia.
Kim CW; Aronow WS; Dutta T; Frenkel D; Frishman WH
Cardiol Rev; 2020; 28(6):325-331. PubMed ID: 31934898
[TBL] [Abstract][Full Text] [Related]
2. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
Watanabe H; Knollmann BC
J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
[TBL] [Abstract][Full Text] [Related]
3. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Ruan Y; Priori SG
Prog Cardiovasc Dis; 2008; 51(1):23-30. PubMed ID: 18634915
[TBL] [Abstract][Full Text] [Related]
4. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
5. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
6. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
[TBL] [Abstract][Full Text] [Related]
7. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
[TBL] [Abstract][Full Text] [Related]
8. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
[TBL] [Abstract][Full Text] [Related]
10. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
[TBL] [Abstract][Full Text] [Related]
11. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
Katz G; Arad M; Eldar M
Curr Probl Cardiol; 2009 Jan; 34(1):9-43. PubMed ID: 19068246
[TBL] [Abstract][Full Text] [Related]
12. A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations.
de la Fuente S; Van Langen IM; Postma AV; Bikker H; Meijer A
Pacing Clin Electrophysiol; 2008 Jul; 31(7):916-9. PubMed ID: 18684293
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
Pflaumer A; Davis AM
Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
[TBL] [Abstract][Full Text] [Related]
16. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Colombi B; Raytcheva-Buono EV; Bloise R; Priori SG
Herz; 2007 May; 32(3):212-7. PubMed ID: 17497254
[TBL] [Abstract][Full Text] [Related]
17. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C
Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588
[TBL] [Abstract][Full Text] [Related]
18. Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation.
Itoh H; Murayama T; Kurebayashi N; Ohno S; Kobayashi T; Fujii Y; Watanabe M; Ogawa H; Anzai T; Horie M
J Electrocardiol; 2021; 69():111-118. PubMed ID: 34656916
[TBL] [Abstract][Full Text] [Related]
19. Catecholaminergic polymorphic ventricular tachycardia.
Leenhardt A; Denjoy I; Guicheney P
Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):1044-52. PubMed ID: 23022705
[No Abstract] [Full Text] [Related]
20. Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: A Translational Perspective for the Clinician-Scientist.
Kallas D; Lamba A; Roston TM; Arslanova A; Franciosi S; Tibbits GF; Sanatani S
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
